Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Anticancer Drugs
100%
Kinase Inhibitor
100%
Ursolic Acid
100%
Trametinib
37%
Molar Ratio
25%
Pegylated Phospholipids
25%
Combination Therapy
12%
Tumor
12%
Monotherapy
12%
Erlotinib
12%
Cancer Cell Lines
12%
Lipids
12%
Human Cancer
12%
Molecular Interactions
12%
Multidrug Resistance
12%
Crizotinib
12%
Gefitinib
12%
Extrusion
12%
Cholesterol
12%
Medical Applications
12%
Nanocarriers
12%
Synergism
12%
Mitogen-activated Protein Kinase
12%
Fluorescence Immunohistochemistry
12%
Structural Disadvantage
12%
Unilamellar
12%
Co-delivery
12%
Lipid Headgroup
12%
Steric Stabilization
12%
PEG Chain
12%
Xenografted Mice
12%
Resistance Effect
12%
In(III)
12%
Foretinib
12%
Passive Tumor Targeting
12%
Refametinib
12%
Dipalmitoylphosphatidylcholine
12%
Novel Type
12%
Medicine and Dentistry
Anticarcinogen
100%
Phosphotransferase Inhibitor
100%
Drug Carrier
100%
Ursolic Acid
100%
Trametinib
37%
Neoplasm
25%
Lipid
25%
Phospholipid
25%
Combination Therapy
12%
Cancer
12%
Monotherapy
12%
Erlotinib
12%
Polyethylene Glycol
12%
Immunohistochemistry
12%
Multidrug Resistance
12%
Cancer Cell Line
12%
Gefitinib
12%
Crizotinib
12%
Nanocarrier
12%
Foretinib
12%
Refametinib
12%
Mitogen-Activated Protein Kinase
12%
Dipalmitoylphosphatidylcholine
12%
Cholesterol
12%